insights_auto
Why is ABVX down 3.67%?
Dive Deeperchevron_right
ABVX:NASDAQ
Abivax SA
$95.39
arrow_downward
-3.67%(-3.63) 1D
Oct 1, 12:08:39 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$96.60
High
$97.12
Low
$93.87
Mkt. cap
7.37B
Avg. vol.
1.24M
Volume
493.88K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.53M
No. of employees
98
Open
$96.60
High
$97.12
Low
$93.87
Mkt. cap
7.37B
Avg. vol.
1.24M
Volume
493.88K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.53M
No. of employees
98
News stories
From web sources and news partners
Ideal Investisseur
·
5 hours ago
Abivax stock drops 12.9% over one month as shorts cover positions
TipRanks
·
19 hours ago
Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026
Stock Titan
·
20 hours ago
Researchers will present three-year data on a drug for ulcerative colitis
Benzinga
·
1 day ago
10 Health Care Stocks Whale Activity In Today’s Session
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com